MainStreet Investment Advisors LLC Takes $697,000 Position in Eli Lilly And Co (NYSE:LLY)

MainStreet Investment Advisors LLC purchased a new stake in shares of Eli Lilly And Co (NYSE:LLY) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 5,023 shares of the company’s stock, valued at approximately $697,000.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Pacitti Group Inc. bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at about $25,000. Stonebridge Financial Planning Group LLC increased its position in shares of Eli Lilly And Co by 70.0% during the first quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock valued at $25,000 after buying an additional 70 shares during the period. Sugarloaf Wealth Management LLC bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at about $26,000. Truvestments Capital LLC bought a new stake in shares of Eli Lilly And Co during the first quarter valued at about $27,000. Finally, Solstein Capital LLC bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at about $34,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Several research firms recently weighed in on LLY. Cantor Fitzgerald upped their price objective on shares of Eli Lilly And Co from $156.00 to $185.00 and gave the stock an “overweight” rating in a research report on Friday, April 24th. Cfra upped their price objective on shares of Eli Lilly And Co from $146.00 to $167.00 and gave the stock a “hold” rating in a research report on Friday, April 24th. UBS Group cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $157.00 to $158.00 in a research report on Monday, April 20th. Goldman Sachs Group upgraded shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price objective on the stock in a research report on Wednesday, March 11th. Finally, Zacks Investment Research decreased their price objective on shares of Eli Lilly And Co to $156.00 in a research report on Wednesday, April 29th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Eli Lilly And Co presently has a consensus rating of “Buy” and an average target price of $158.64.

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $139.11, for a total transaction of $29,213,100.00. Following the completion of the sale, the insider now owns 113,441,468 shares of the company’s stock, valued at $15,780,842,613.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total value of $3,503,750.00. Following the sale, the senior vice president now directly owns 44,773 shares of the company’s stock, valued at approximately $6,274,935.95. The disclosure for this sale can be found here. In the last ninety days, insiders sold 906,320 shares of company stock valued at $132,984,238. 0.09% of the stock is owned by insiders.

LLY traded down $1.12 during midday trading on Friday, hitting $151.16. The stock had a trading volume of 2,322,495 shares, compared to its average volume of 2,875,585. The company has a market cap of $145.65 billion, a P/E ratio of 24.99, a price-to-earnings-growth ratio of 1.82 and a beta of 0.25. The business has a fifty day moving average of $152.85 and a 200 day moving average of $136.00. The company has a debt-to-equity ratio of 4.37, a quick ratio of 0.86 and a current ratio of 1.11. Eli Lilly And Co has a 1 year low of $101.36 and a 1 year high of $164.90.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Thursday, April 23rd. The company reported $1.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.48 by $0.27. The business had revenue of $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. Eli Lilly And Co’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.33 earnings per share. On average, equities research analysts anticipate that Eli Lilly And Co will post 6.81 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $0.74 dividend. This represents a $2.96 annualized dividend and a yield of 1.96%. The ex-dividend date is Thursday, May 14th. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: What is Blockchain?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.